Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 1
2024 3
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean dilillo m (26 results)?
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Tolaney SM, Tarantino P, Graham N, Tayob N, Parè L, Villacampa G, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Barroso-Sousa R, Villagrasa P, DeMeo M, DiLullo M, Zanudo JGT, Weiss J, Wagle N, Partridge AH, Waks AG, Hudis CA, Krop IE, Burstein HJ, Prat A, Winer EP. Tolaney SM, et al. Among authors: dilullo m. Lancet Oncol. 2023 Mar;24(3):273-285. doi: 10.1016/S1470-2045(23)00051-7. Lancet Oncol. 2023. PMID: 36858723 Clinical Trial.
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
Tarantino P, Tayob N, Villacampa G, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Garrett AM, Marcom PK, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Ruddy KJ, Waks AG, DeMeo M, Burstein HJ, Partridge AH, Dell'Orto P, Russo L, Krause E, Newhouse DJ, Kurt BB, Mittendorf EA, Schneider B, Prat A, Winer EP, Krop IE, Tolaney SM; Consortium of the TBCRC Translational Investigators; TBCRC Translational Investigators. Tarantino P, et al. J Clin Oncol. 2024 Nov;42(31):3652-3665. doi: 10.1200/JCO.23.02170. Epub 2024 Jun 27. J Clin Oncol. 2024. PMID: 38935923 Free PMC article. Clinical Trial.
Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies.
Jovanović B, Church SE, Gorman KM, North K, Richardson ET 3rd, DiLullo M, Attaya V, Kasparian J, Mohammed-Abreu A, Kirkner G, Hughes ME, Lin NU, Mittendorf EA, Schnitt SJ, Tolaney SM, Goel S. Jovanović B, et al. Among authors: dilullo m. Clin Cancer Res. 2024 Oct 15;30(20):4768-4779. doi: 10.1158/1078-0432.CCR-23-1242. Clin Cancer Res. 2024. PMID: 39136550 Free PMC article.
A Phase II Study of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab for Central Nervous System Metastases in Patients with HER2-Positive Breast Cancer.
Giordano A, Kumthekar PU, Jin Q, Binboga Kurt B, Ren S, Li T, Leone JP, Mittendorf EA, Pereslete AM, Sharp L, Davis R, DiLullo M, Tayob N, Mayer EL, Winer EP, Tolaney SM, Lin NU. Giordano A, et al. Among authors: dilullo m. Clin Cancer Res. 2024 Nov 1;30(21):4856-4865. doi: 10.1158/1078-0432.CCR-24-1161. Clin Cancer Res. 2024. PMID: 39226397 Free PMC article. Clinical Trial.
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS).
Barroso-Sousa R, Zanudo JGT, Li T, Reddy SM, Emens LA, Kuntz TM, Silva CAC, AlDubayan SH, Chu H, Overmoyer B, Lange P, DiLullo MK, Montesion M, Kasparian J, Hughes ME, Attaya V, Basta A, Lin NU, Tayob N, Jeselsohn R, Mittendorf EA, Tolaney SM. Barroso-Sousa R, et al. Among authors: dilullo mk. Nat Commun. 2025 May 13;16(1):4430. doi: 10.1038/s41467-025-59695-1. Nat Commun. 2025. PMID: 40360544 Free PMC article. Clinical Trial.
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer.
Garrido-Castro AC, Graham N, Ali LR, Herold C, Desrosiers J, Do K, Parsons H, Li T, Goel S, DiLullo M, Wrabel E, Williams AJ, Liu JF, Mittendorf EA, Dougan SK, Tayob N, Shapiro GI, Tolaney SM. Garrido-Castro AC, et al. Among authors: dilullo m. J Immunother Cancer. 2025 Feb 25;13(2):e010430. doi: 10.1136/jitc-2024-010430. J Immunother Cancer. 2025. PMID: 40010764 Free PMC article. Clinical Trial.
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers.
Lynce F, Martínez-Sáez O, Walbaum B, Brasó-Maristany F, Waks AG, Villagrasa P, Villacampa Javierre G, Sanfeliu E, Galván P, Paré L, Anderson LM, Perou CM, Parker JS, Vivancos A, DiLullo MK, Pernas S, Winer EP, Overmoyer B, Mittendorf EA, Bueno-Muiño C, Martín M, Prat A, Tolaney SM. Lynce F, et al. Among authors: dilullo mk. ESMO Open. 2025 Feb;10(2):104100. doi: 10.1016/j.esmoop.2024.104100. Epub 2025 Jan 17. ESMO Open. 2025. PMID: 39826476 Free PMC article. Clinical Trial.
Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study.
Fanucci K, Yeh ED, Shi R, Qin L, Bay CP, DiLullo M, Patel A, Moore M, Herbert ZT, Harrison BT, Nakhlis F, Bellon J, Warren L, Guerriero JL, Tolaney SM, Regan M, Overmoyer B, Van Laere S, Lynce F. Fanucci K, et al. Among authors: dilullo m. Breast Cancer Res. 2025 Sep 29;27(1):171. doi: 10.1186/s13058-025-02108-4. Breast Cancer Res. 2025. PMID: 41024110 Clinical Trial.